These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26690199)

  • 1. Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study.
    Porter DP; Daeumer M; Thielen A; Chang S; Martin R; Cohen C; Miller MD; White KL
    Viruses; 2015 Dec; 7(12):6360-70. PubMed ID: 26690199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    J Acquir Immune Defic Syndr; 2014 Mar; 65(3):318-26. PubMed ID: 24525469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
    Nelson MR; Elion RA; Cohen CJ; Mills A; Hodder SL; Segal-Maurer S; Bloch M; Garner W; Guyer B; Williams S; Chuck S; Vanveggel S; Deckx H; Stevens M
    HIV Clin Trials; 2013; 14(3):81-91. PubMed ID: 23835510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
    Behrens G; Rijnders B; Nelson M; Orkin C; Cohen C; Mills A; Elion RA; Vanveggel S; Stevens M; Rimsky L; Thorpe D; Bosse M; White K; Zhong L; DeMorin J; Chuck SK
    AIDS Patient Care STDS; 2014 Apr; 28(4):168-75. PubMed ID: 24660840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
    Margot NA; Enejosa J; Cheng AK; Miller MD; McColl DJ;
    J Acquir Immune Defic Syndr; 2009 Oct; 52(2):209-21. PubMed ID: 19644384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
    Cohen C; Wohl D; Arribas JR; Henry K; Van Lunzen J; Bloch M; Towner W; Wilkins E; Ebrahimi R; Porter D; White K; Walker I; Chuck S; De-Oertel S; Fralich T
    AIDS; 2014 Apr; 28(7):989-97. PubMed ID: 24508782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.
    Porter DP; Toma J; Tan Y; Solberg O; Cai S; Kulkarni R; Andreatta K; Lie Y; Chuck SK; Palella F; Miller MD; White KL
    HIV Clin Trials; 2016 Feb; 17(1):29-37. PubMed ID: 26899540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
    Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
    AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline antiretroviral resistance mutations and treatment-emergent resistance in HIV-1 RNA-suppressed patients switching to EVG/COBI/FTC/TDF or continuing on their PI-, NNRTI-, or RAL-based regimen.
    Andreatta K; Kulkarni R; Abram ME; Nguyen T; Cao H; Miller MD; White KL
    J Acquir Immune Defic Syndr; 2015 Apr; 68(5):519-26. PubMed ID: 25559592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
    Palella FJ; Fisher M; Tebas P; Gazzard B; Ruane P; Van Lunzen J; Shamblaw D; Flamm J; Ebrahimi R; Porter D; White K; Hindman J; Elbert E; De-Oertel S; Fralich T
    AIDS; 2014 Jan; 28(3):335-44. PubMed ID: 24670520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF through 96 weeks.
    Porter DP; Kulkarni R; Garner W; Miller MD; White KL
    Antivir Ther; 2017; 22(6):495-502. PubMed ID: 28091393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study.
    van Lunzen J; Antinori A; Cohen CJ; Arribas JR; Wohl DA; Rieger A; Rachlis A; Bloch M; Segal-Maurer S; Garner W; Porter D; Bosse M; Piontkowsky D; Chuck SK; De-Oertel S
    AIDS; 2016 Jan; 30(2):251-9. PubMed ID: 26684822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
    AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
    Domingo P; Ribera E
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).
    Kulkarni R; Hodder SL; Cao H; Chang S; Miller MD; White KL
    HIV Clin Trials; 2017 Jul; 18(4):164-173. PubMed ID: 28891788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.
    Hagins D; Orkin C; Daar ES; Mills A; Brinson C; DeJesus E; Post FA; Morales-Ramirez J; Thompson M; Osiyemi O; Rashbaum B; Stellbrink HJ; Martorell C; Liu H; Liu YP; Porter D; Collins SE; SenGupta D; Das M
    HIV Med; 2018 Nov; 19(10):724-733. PubMed ID: 30101539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.
    Armenia D; Di Carlo D; Calcagno A; Vendemiati G; Forbici F; Bertoli A; Berno G; Carta S; Continenza F; Fedele V; Bellagamba R; Cicalini S; Ammassari A; Libertone R; Zaccarelli M; Ghisetti V; Andreoni M; Ceccherini-Silberstein F; Bonora S; Di Perri G; Antinori A; Perno CF; Santoro MM
    J Antimicrob Chemother; 2017 Mar; 72(3):855-865. PubMed ID: 27999048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Resistance profile of rilpivirine].
    Imaz A; García F; di Yacovo S; Llibre JM
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():36-43. PubMed ID: 24252532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.